Cell line · CVCL_0589
Papers89
3 more articles give this line's RRID in its Methods without naming the line nearby, so they are not listed.
1 to 20 of 89
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Greatwall kinase regulates acute myeloid leukaemia cell division through a non-canonical mechanism. | EMBO Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Novel noscapine derivative induces AML differentiation by dual-engaging DHODH and mitochondrial lipids to trigger a metabolic-epigenetic-transcriptional cascade. | Acta Pharm Sin B | 2026 | Its Methods give the RRID and name the line | PubMed | |
| DHX15 affects AML1-ETO9a splicing together with HNRNPL, RBM33 in AML1-ETO-positive acute myeloid leukaemia. | Br J Haematol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Enhancement of CD117-Targeted Bispecific T-cell Engagement by CD33-Targeted Bispecific T-cell Costimulation in Acute Myeloid Leukemia. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A Bispecific Anti-Fluorescein × Anti-CD3 T-cell Engager in Combination with Fluoresceinated Adaptors Enables Lysis of AML Cells. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Transient mRNA-based CD117 CAR T cells effectively target acute myeloid leukemia in vitro for potential use as a preconditioning strategy. | Immunooncol Technol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ΔNp73 isoform defines a TP53-mutant-like poor-risk subgroup of acute myeloid leukemia. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Chronic ER Stress Triggers Cell-Surface Chaperones as the Therapeutic Targets of CAR Cells in Acute Myeloid Leukemia. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Predictors of response and rational combinations for the novel MCL-1 inhibitor MIK665 in acute myeloid leukemia. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Balancing Activation and Repression: CoREST-p300 Antagonism Controls Retinoic Acid-Driven Differentiation in AML. | bioRxiv | 2025 | Its Methods give the RRID and name the line | PubMed | |
| A novel strategy to target metabolic dependencies in acute myeloid leukemia. | Cell Death Dis | 2025 | Its Methods give the RRID and name the line | PubMed | |
| The bispecific innate cell engager AFM28 eliminates CD123+ leukemic stem and progenitor cells in AML and MDS. | Nat Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| TOR signalling mediates the collective movement of border cells in Drosophila oogenesis. | Development | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Jab1 promotes immune evasion and progression in acute myeloid leukemia models under oxidative stress. | J Clin Invest | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Catalytic Inhibition of KAT6/KAT7 Enhances the Efficacy and Overcomes Primary and Acquired Resistance to Menin Inhibitors in MLL Leukemia. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| CD97-directed CAR-T cells with enhanced persistence eradicate acute myeloid leukemia in diverse xenograft models. | Cell Rep Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| A niche driven mechanism determines response and a mutation-independent therapeutic approach for myeloid malignancies. | Cancer Cell | 2025 | Its Methods give the RRID and name the line | PubMed | |
| PLK1 Inhibition Induces Synthetic Lethality in Fanconi Anemia Pathway-Deficient Acute Myeloid Leukemia. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer. | Mol Cancer Ther | 2025 | Its Methods give the RRID and name the line | PubMed | |
| PROTAC-Mediated GSPT1 Degradation Impairs the Expression of Fusion Genes in Acute Myeloid Leukemia. | Cancers (Basel) | 2025 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0589/papers